利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

890 条记录 (耗时 0.096 秒)

    Cytokines and Cytokine Receptors With Reduced Immunocencity
    73.
    发明申请
    Cytokines and Cytokine Receptors With Reduced Immunocencity 审中-公开
    细胞因子和细胞因子受体具有减少的免疫活性

    公开(公告)号：US20090258832A1

    公开(公告)日：2009-10-15

    申请号：US12404063

    申请日：2009-03-13

    申请人： Scott D. Power ,  Fiona A. Harding

    发明人： Scott D. Power ,  Fiona A. Harding

    IPC分类号： A61K38/16 ,  C07K14/00 ,  C07H21/00 ,  C12N15/74 ,  C12N1/00 ,  A61K31/7088 ,  A61P37/02

    CPC分类号： G01N33/6878 ,  A61K38/00 ,  C07K14/505 ,  C07K14/524 ,  C07K14/565 ,  C07K14/7151 ,  G01N33/505 ,  G01N33/56972 ,  G01N33/6863

    摘要： The present invention provides methods for the identification of CD4+ T-cell epitopes in the sequences of various proteins, namely, human cytokines and cytokine receptors, as well as the production of peptides which when incorporated into the protein sequence, are no longer capable of initiating the CD4+ T-cell response. In some embodiments, the present invention provides means and compositions suitable for reducing the immunogenicity of cytokines and cytokines receptors such as interferon-β, soluble tumor necrosis factor receptor-1, erythropoietin, and thrombopoietin.

    摘要翻译： 本发明提供了鉴定各种蛋白质序列中的CD4 + T细胞表位的方法，即人类细胞因子和细胞因子受体，以及当其并入蛋白质序列时不再能起始的肽的产生 CD4 + T细胞应答。 在一些实施方案中，本发明提供适于降低细胞因子和细胞因子受体如干扰素-β，可溶性肿瘤坏死因子受体-1，促红细胞生成素和血小板生成素的免疫原性的方法和组合物。

    USE OF LONG-ACTING RECOMBINANT HUMAN SOLUBLE TUMOR NECROSIS FACTOR ALPHA RECEPTOR IN MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT AND/OR PROPHYLAXIS OF HEPATIC FAILURE
    75.
    发明申请
    USE OF LONG-ACTING RECOMBINANT HUMAN SOLUBLE TUMOR NECROSIS FACTOR ALPHA RECEPTOR IN MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT AND/OR PROPHYLAXIS OF HEPATIC FAILURE 有权
    使用长效重组人类可溶性肿瘤坏死因子ALPHA受体在制造治疗和/或预防HEPATIC失败的药物

    公开(公告)号：US20090176702A1

    公开(公告)日：2009-07-09

    申请号：US12090037

    申请日：2006-10-13

    申请人： Hai Li

    发明人： Hai Li

    IPC分类号： A61K38/16

    CPC分类号： C07K14/7151 ,  A61K38/00

    摘要： The present invention belongs to the field of the application of genetic engineering and gene function, and it is directed to a new medical use of the gene encoding the recombinant soluble tumor necrosis factor α receptor (HusTNFR). The present invention made intervention to fulminant hepatic failure in mice by use of the long-acting recombinant human soluble tumor necrosis factor α receptor and the classic animal models of acute and sub-acute hepatic failure. The results showed that the long-acting soluble tumor necrosis factor αreceptor of the present invention has a half-life extended more than 10 times, and it significantly decreased the mortality of model animals and has superior therapeutic effect for the treatment and/or prophylaxis of acute and sub-acute hepatic failure in model animals. These receptors have a noticeable therapeutic effect for the treatment and/or prophylaxis of acute and sub-acute hepatic failure in comparison with the non-long-acting HusTNFR.

    摘要翻译： 本发明属于遗传工程和基因功能的应用领域，涉及编码重组可溶性肿瘤坏死因子α受体（HusTNFR）的基因的新医学应用。 本发明通过使用长效重组人可溶性肿瘤坏死因子α受体和急性和亚急性肝衰竭的经典动物模型，对小鼠暴发性肝衰竭进行干预。 结果表明，本发明的长效可溶性肿瘤坏死因子受体的半衰期延长了10倍以上，显着降低了模型动物的死亡率，并且对治疗和/或预防 模型动物急性和亚急性肝衰竭。 与非长效HusTNFR相比，这些受体对治疗和/或预防急性和亚急性肝衰竭具有明显的治疗作用。

    Human Tumor Necrosis Factor Receptor-Like 2
    76.
    发明申请
    Human Tumor Necrosis Factor Receptor-Like 2 失效
    人类肿瘤坏死因子受体样2

    公开(公告)号：US20090131319A1

    公开(公告)日：2009-05-21

    申请号：US12235837

    申请日：2008-09-23

    申请人： Jian Ni ,  Craig A. Rosen ,  Reiner L. Gentz ,  Sally Doreen Patricia Lyn ,  Mark Robert Hurle

    发明人： Jian Ni ,  Craig A. Rosen ,  Reiner L. Gentz ,  Sally Doreen Patricia Lyn ,  Mark Robert Hurle

    IPC分类号： A61K38/16 ,  C07H21/04 ,  C12N15/63 ,  C12N15/09 ,  C12N5/00 ,  C12P21/06 ,  C07K14/00 ,  C07K16/00

    CPC分类号： C07K14/7151

    摘要： The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding a human TR2 receptor and two splice variants thereof. TR2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR2 receptors.

    摘要翻译： 本发明涉及肿瘤坏死因子家族受体的新成员。 本发明提供编码人TR2受体的分离的核酸分子及其两个剪接变体。 还提供TR2多肽，载体，宿主细胞和用于制备它们的重组方法。 本发明还涉及用于鉴定TR2受体活性的激动剂和拮抗剂的筛选方法。 还提供了用于检测与TR2受体的异常表达相关的疾病状态的诊断方法。 还提供了治疗与表达TR2受体的细胞的异常增殖和分化相关的疾病状态的治疗方法。

    Methods for purifying protein
    79.
    发明授权
    Methods for purifying protein 有权
    蛋白质纯化方法

    公开(公告)号：US07476722B2

    公开(公告)日：2009-01-13

    申请号：US11520921

    申请日：2006-09-13

    申请人： Ganesh Vedantham ,  Clayton Brooks, III ,  Joanne M Reeder ,  Andrew M Goetze

    发明人： Ganesh Vedantham ,  Clayton Brooks, III ,  Joanne M Reeder ,  Andrew M Goetze

    IPC分类号： A61K39/395 ,  C07K16/00 ,  C07K16/46 ,  C07K1/16 ,  C07K1/22

    CPC分类号： C07K14/7151 ,  C07K1/16 ,  C07K1/22 ,  C07K14/70575 ,  C07K2319/00 ,  C07K2319/30

    摘要： A method is provided for separating a protein from one or more other proteins using hydroxyapatite chromatography in which the protein does not bind to hydroxyapatite but the other protein(s) does. In some embodiments, a second protein affixed to a solid support has been used previously to purify the protein by affinity chromatography, and small amounts of the second protein are introduced in the sample during this process. The protein being purified can comprise at least one constant antibody immunoglobulin domain. The second protein can bind to proteins comprising such a domain.

    摘要翻译： 提供了一种使用羟基磷灰石层析从蛋白质与一种或多种其他蛋白质分离蛋白质的方法，其中蛋白质不结合羟基磷灰石，但是其它蛋白质不结合羟磷灰石。 在一些实施方案中，先前已经使用固定在固体支持物上的第二种蛋白质通过亲和层析纯化蛋白质，并且在该过程中将少量的第二种蛋白质引入样品中。 待纯化的蛋白质可以包含至少一个恒定的抗体免疫球蛋白结构域。 第二种蛋白质可以结合包含这种结构域的蛋白质。